ArticleThe British journal of surgery2019
Safety and efficacy of transarterial embolization of hepatocellular adenomas.
Article in The British journal of surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- To Systematically Evaluate and Analyze the Efficacy and Safety of Transcatheter Arterial Chemoembolization (TACE) in the Treatment of Primary Liver Cancer.Journal of healthcare engineering · 2022Pooled it
- Multifocal hemorrhagic hepatocellular adenomas following vigorous physical exertion: Radiologic-pathologic correlation and endovascular management.Radiology case reports · 2026Article
- Nonoperative Management of Hepatic Adenomas: A Review.Journal of gastrointestinal cancer · 2026Review
- Hepatic adenomatosis leading to liver failure and symptomatic extrinsic cardiac compression treated with liver transplantation: a case report and literature review.Frontiers in transplantation · 2026Article
- Case Report: Hepatocellular adenoma due to long-term oral stanozolol administration.Frontiers in medicine · 2025Article
- The application of interventional methods in control of blood loss during giant upper extremity tumor resection.BMC surgery · 2024Article
- Disappearance of Hepatocellular Adenoma in a Patient with Cornelia de Lange Syndrome after Treatment with Transcatheter Arterial Embolization.Internal medicine (Tokyo, Japan) · 2024Article
- Development of a set of patient reported outcome measures for patients with benign liver tumours and cysts: patient focus groups and systematic review.Journal of patient-reported outcomes · 2022Article
- Benign liver tumours: understanding molecular physiology to adapt clinical management.Nature reviews. Gastroenterology & hepatology · 2022Review
- The prognostic value and clinical significance of mitophagy-related genes in hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Scoping review of clinical practice guidelines on the management of benign liver tumours.BMJ open gastroenterology · 2021Article
- Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeons' Perspective.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Article
- Spontaneous hepatic haemorrhage secondary to ruptured hepatocellular adenoma in a young male patient.BMJ case reports · 2020Article
- New insights in the management of Hepatocellular Adenoma.Liver international : official journal of the International Association for the Study of the Liver · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular adenoma (HCA) larger than 5 cm in diameter has an increased risk of haemorrhage and malignant transformation, and is considered an indication for resection. As an alternative to resection, transarterial embolization (TAE) may play a role in prevention of complications of HCA, but its safety and efficacy are largely unknown. The aim of this study was to assess outcomes and postembolization effects of selective TAE in the management of HCA.
methodsThis retrospective, multicentre cohort study included patients aged at least 18 years, diagnosed with HCA and treated with TAE. Patient characteristics, 30-day complications, tumour size before and after TAE, symptoms before and after TAE, and need for secondary interventions were analysed.
resultsOverall, 59 patients with a median age of 33.5 years were included from six centres; 57 of the 59 patients were women. Median tumour size at time of TAE was 76 mm. Six of 59 patients (10 per cent) had a major complication (cyst formation or sepsis), which could be resolved with minimal therapy, but prolonged hospital stay. Thirty-four patients (58 per cent) were symptomatic at presentation. There were no significant differences in symptoms before TAE and symptoms evaluated in the short term (within 3 months) after TAE (P = 0·134). First follow-up imaging was performed a median of 5·5 months after TAE and showed a reduction in size to a median of 48 mm (P < 0·001).
conclusionTAE is safe, can lead to adequate size reduction of HCA and, offers an alternative to resection in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.